These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16266193)

  • 1. Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior.
    Hedelin H; Ströberg P
    Drugs; 2005; 65(16):2245-51. PubMed ID: 16266193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment options for erectile dysfunction in patients with diabetes mellitus.
    Basu A; Ryder RE
    Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.
    Ljunggren C; Hedelin H; Salomonsson K; Ströberg P
    J Sex Med; 2008 Feb; 5(2):469-75. PubMed ID: 18086159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
    Hatzimouratidis K; Salonia A; Adaikan G; Buvat J; Carrier S; El-Meliegy A; McCullough A; Torres LO; Khera M
    J Sex Med; 2016 Apr; 13(4):465-88. PubMed ID: 27045254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging oral drugs for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
    Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for erectile dysfunction.
    Eardley I; Donatucci C; Corbin J; El-Meliegy A; Hatzimouratidis K; McVary K; Munarriz R; Lee SW
    J Sex Med; 2010 Jan; 7(1 Pt 2):524-40. PubMed ID: 20092451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
    Wright PJ
    Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE5 inhibitors: are there differences?
    Carson CC
    Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of erectile dysfunction.
    Montorsi F; Salonia A; Deho' F; Cestari A; Guazzoni G; Rigatti P; Stief C
    BJU Int; 2003 Mar; 91(5):446-54. PubMed ID: 12603396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment.
    Al-Shaiji TF; Brock GB
    Curr Pharm Des; 2009; 15(30):3486-95. PubMed ID: 19860694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options].
    Sperling H; Lümmen G; Schneider T; Rübben H
    Herz; 2003 Jun; 28(4):314-24. PubMed ID: 12825147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future options for combination therapy in the management of erectile dysfunction in older men.
    Sommer F; Engelmann U
    Drugs Aging; 2004; 21(9):555-64. PubMed ID: 15260511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraurethral alprostadil for erectile dysfunction: a review of the literature.
    Costa P; Potempa AJ
    Drugs; 2012 Dec; 72(17):2243-54. PubMed ID: 23170913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
    Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
    BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
    Mirone V; Fusco F; Rossi A; Sicuteri R; Montorsi F
    BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.